Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cholangiocarcinoma 4Neoplasm Metastasis 2Carcinoma, Transitional Cell 2Acrocephalosyndactylia 2Stomach Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

tanespimycin 1pemigatinib 1pembrolizumab 1MLN8054 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Malignancies × pemigatinib × Clear all
NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated
10 enrolled 9 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡